Risk of adverse outcomes from COVID-19 is higher for patients with cancer
1. COVID-19 patients with cancer had increased rates of hospitalization, ICU stay, and mortality than patients without cancer. 2. Patients...
Maintenance olaparib, compared with placebo, reduces the risk of disease progression in patients with advanced BRCA mutation ovarian cancer
1. Median progression-free survival was 56.0 months in the olaparib group and was 13.8 months in the placebo group. 2....
Nivolumab is a potential treatment option for patients with relapsing malignant mesothelioma
1. Overall survival was 6.9 months in the placebo group and 10.2 months in the nivolumab group. 2. Progression free...
Mobocertinib is a tolerable and possible treatment option for patients with EGFR exon 20 insertion mutated advanced non-small-cell lung cancer
1. Overall response rate was 28% and 35% in the platinum pretreated cohort (PPP) and 25% and 32% in the...
Camrelizumab with apatinib is a well-tolerated treatment for chemo-refractory or relapsed gestational trophoblastic neoplasia
1. Camrelizumab and apatinib treatment provided a 55% objective response rate 2. A complete response was observed in 50% of...
Ivosidenib improves overall survival in IDH1-mutant advanced cholangiocarcinoma as compared to placebo
1. Patients receiving Ivosidenib had longer overall survival as compared to patients on placebo. 2. Quality of life measures favored...
Adavosertib compared with active monitoring is potentially effective against TP53/RAS-mutant metastatic colorectal cancer.
1. Patients on adavosertib had both increased progression-free survival and better tumor control, as compared to patients being actively monitored...
Active monitoring compared to maintenance capecitabine is a viable alternative for stable metastatic colorectal cancer
1. Progression-free survival was extended by the use capecitabine as compared to active monitoring, but at the expense of increased...